帕金森病嗅觉障碍的研究进展

doi:10.16352/j.issn.1001-6325.2023.06.0994

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (6): 994-997.doi: 10.16352/j.issn.1001-6325.2023.06.0994

帕金森病嗅觉障碍的研究进展

任鹏, 陈雅丽, 张娴文^*

昆明理工大学医学院, 云南昆明 650500

收稿日期:2022-03-28 修回日期:2022-07-21 出版日期:2023-06-05 发布日期:2023-05-31
通讯作者: ^*xianwen-zhang0717@163.com
基金资助:
国家自然科学基金(81901118)

Olfactory disorder in Parkinson's disease

REN Peng, CHEN Yali, ZHANG Xianwen^*

Medical College, Kunming University of Science and Technology, Kunming 650500, China

Received:2022-03-28 Revised:2022-07-21 Online:2023-06-05 Published:2023-05-31
Contact: ^*xianwen-zhang0717@163.com

摘要/Abstract

摘要： 嗅觉障碍是帕金森病(PD)最常见和最具特征的早期非运动症状,可作为PD诊断的重要依据之一。PD嗅觉障碍的机制非常复杂,是基础和临床研究的难点。病理性α-突触核蛋白的聚集,多巴胺(DA)、乙酰胆碱(ACh)、五羟色胺(5-HT)和炎性反应等神经介质的改变与PD嗅觉障碍的发生密切相关。深入研究PD嗅觉障碍的发病机制,可为治疗提供新思路及新靶点。

关键词: 帕金森病, 嗅觉障碍, α-突触核蛋白, 炎性反应, 神经递质

Abstract: Olfactory dysfunction is the most common early non-motor symptom of Parkinson's disease (PD), which is used as a marker for the diagnosis of PD. The mechanism of olfactory dysfunction is very complex, which is a challenge in the research. The neuromediator such as the accumulation of α-synuclein, dopamine (DA), acetylcholine (ACh), 5-hydroxytryptamine (5-HT) and inflammatory factors are implicated in the olfactory dysfunction in PD. To further study the mechanism of olfactory dysfunction in PD may provide new ideas and therapeutic targets for treatment.

Key words: Parkinson's disease, olfactory dysfunction, α-synuclein, inflammation response, neuromediator

中图分类号:

R730.2

任鹏, 陈雅丽, 张娴文. 帕金森病嗅觉障碍的研究进展[J]. 基础医学与临床, 2023, 43(6): 994-997.

REN Peng, CHEN Yali, ZHANG Xianwen. Olfactory disorder in Parkinson's disease[J]. Basic & Clinical Medicine, 2023, 43(6): 994-997.

参考文献 25

[1]	Roos DS, Klein M, Deeg DJH, et al. Prevalence of prodromal symptoms of Parkinson's disease in the late middle-aged population[J]. J Parkinsons Dis, 2022,12:967-974.
[2]	Nabizadeh F, Pirahesh K, Khalili E. Olfactory dysfunc-tion is associated with motor function only in tremor-dominant Parkinson's disease[J]. Neurol Sci, 2022,2:1-9.
[3]	Solla P, Masala C, Liscia A, et al. Sex-related differ-ences in olfactory function and evaluation of possible confounding factors among patients with Parkinson's disease[J]. J Neurol, 2020,267:57-63.
[4]	Lee YH, Bak Y, Park CH, et al. Patterns of olfactory functional networks in Parkinson's disease dementia and Alzheimer's dementia[J]. Neurobiol Aging, 2020,89:63-70.
[5]	Marrero-Gonzalez P, Iranzo A, Bedoya D, et al. Prodro-mal Parkinson disease in patients with idiopathic hyposmia[J]. J Neurol, 2020,267:3673-3682.
[6]	Zhou Y, He R, Zhao Y, et al. Olfactory dysfunction and its relationship with clinical features of Parkinson's disease[J]. Front Neurol, 2020,11:1-9.
[7]	Glover A, Pillai L, Dhall R, et al. Olfactory deficits in the freezing of gait phenotype of Parkinson's disease[J]. Front Neurol, 2021,12:1-9.
[8]	Roh H, Kang J, Koh SB, et al. Hippocampal volume is related to olfactory impairment in Parkinson's disease[J]. J Neuroimaging, 2021,31:1176-1183.
[9]	Lin CY, Chang TY, Chang MH. Dysosmia Is a predictor of motor function and quality of life in patients with Parkinson's disease[J]. J Pers Med, 2022,12:1-13.
[10]	Wakabayashi K. Where and how alpha-synuclein pathology spreads in Parkinson's disease[J]. Neuropathology, 2020,40:415-425.
[11]	Uemura N, Ueda J, Yoshihara T, et al. alpha-synuclein spread from olfactory bulb causes hyposmia, anxiety, and memory loss in BAC-SNCA mice[J]. Mov Disord, 2021,36:2036-2047.
[12]	Li R, Lu Y, Zhang Q, et al. Piperine promotes autophagy flux by P2RX4 activation in SNCA/alpha-synuclein-induced Parkinson disease model[J]. Autophagy, 2022,18:559-575.
[13]	Kulkarni AS, Del Mar Cortijo M, Roberts ER, et al. Perturbation of in vivo neural activity following alpha-synuclein seeding in the olfactory bulb[J]. J Parkinsons Dis, 2020,10:1411-1427.
[14]	Pass T, Assfalg M, Tolve M, et al. The impact of mitochondrial dysfunction on dopaminergic neurons in the olfactory bulb and odor detection[J]. Mol Neurobiol, 2020,57:3646-3657.
[15]	Ma K, Han C, Zhang G, et al. Reduced VMAT2 expression exacerbates the hyposmia in the MPTP model of Parkinson's disease[J]. Biochem Biophys Res Commun, 2019,513:306-312.
[16]	Zhang W, Sun C, Shao Y, et al. Partial depletion of dopaminergic neurons in the substantia nigra impairs olfaction and alters neural activity in the olfactory bulb[J]. Sci Rep, 2019,9:254-267.
[17]	Jiang S, Berger S, Hu Y, et al. Alterations of the motor and olfactory functions related to Parkinson's disease in transgenic mice with a VMAT2-deficiency in dopaminergic neurons[J]. Front Neurosci, 2020,14:356-367.
[18]	Oh E, Park J, Youn J, et al. Olfactory dysfunction in early Parkinson's disease is associated with short latency afferent inhibition reflecting central cholinergic dysfunction[J]. Clin Neurophysiol, 2017,128:1061-1068.
[19]	Yang J, Lv DJ, Li LX, et al. Nicotine improved the olfactory impairment in MPTP-induced mouse model of Parkinson's disease[J]. Neurotoxicology, 2019,73:175-182.
[20]	Fullard ME, Morley JF, Duda JE. Olfactory dysfunction as an early biomarker in Parkinson's disease[J]. Neurosci Bull, 2017,33:515-525.
[21]	Morais LH, Hara DB, Bicca MA, et al. Early signs of colonic inflammation, intestinal dysfunction, and olfactory impairments in the rotenone-induced mouse model of Parkinson's disease[J]. Behav Pharmacol, 2018,29:199-210.
[22]	Cui C, Hong H, Shi Y, et al. Vancomycin pretreatment on MPTP-Induced Parkinson's disease mice exerts neuroprotection by suppressing inflammation both in brain and gut[J]. J Neuroimmune Pharmacol, 2022,1:1-18.
[23]	Niu H, Wang Q, Zhao W, et al. IL-1beta/IL-1R1 signaling induced by intranasal lipopolysaccharide infusion regulates alpha-synuclein pathology in the olfactory bulb, substantia nigra and striatum[J]. Brain Pathol, 2020,30:1102-1118.
[24]	Zhang X, Huang W, Shao Q, et al. Drp1, a potential therapeutic target for Parkinson's disease, is involved in olfactory bulb pathological alteration in the Rotenone-induced rat model[J]. Toxicol Lett, 2020,325:1-13.
[25]	Chen Y, Zhang QS, Shao QH, et al. NLRP3 inflammasome pathway is involved in olfactory bulb pathological alteration induced by MPTP[J]. Acta Pharmacol Sin, 2019,40:991-998.

帕金森病嗅觉障碍的研究进展

Olfactory disorder in Parkinson's disease

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 25

相关文章 15

编辑推荐

Metrics

本文评价

[1]	于曼殊, 赵晓敏, 邱明月, 刘春冉, 那日苏. 牙源性干细胞治疗帕金森病的研究进展[J]. 基础医学与临床, 2024, 44(9): 1298-1302.
[2]	孟德权, 秦欣, 陈玲, 覃军. 白术多糖抑制重症肺炎模型大鼠的炎性反应[J]. 基础医学与临床, 2024, 44(9): 1263-1268.
[3]	蒋苏, 吕新翔, 崔艳红, 吕李婷, 李东霞. 吴茱萸碱对特应性皮炎模型大鼠的治疗作用[J]. 基础医学与临床, 2024, 44(9): 1256-1262.
[4]	钱喜锋, 华潞. 炎性细胞与动脉性肺动脉高压血管重塑[J]. 基础医学与临床, 2024, 44(8): 1080-1087.
[5]	高超, 张润菡, 王伟, 赵曼婷, 焦艳, 李喆. 青蒿琥酯调节cGAS-STING信号通路对抑郁症模型小鼠神经炎性反应的影响[J]. 基础医学与临床, 2024, 44(8): 1126-1132.
[6]	张昊, 孙浩, 廖红. 诱导抑郁症患者小胶质细胞炎性反应的机制[J]. 基础医学与临床, 2024, 44(7): 1029-1033.
[7]	霍岩松, 孙海燕, 庞金磊, 郭向飞, 刘亚静, 冉广原, 何明伟. 臭氧联合低温等离子射频消融术对神经根型颈椎病的疗效[J]. 基础医学与临床, 2024, 44(6): 840-844.
[8]	盛琪, 童瑾. CXCL10/CXCR3轴在急性呼吸窘迫综合征中的作用[J]. 基础医学与临床, 2024, 44(6): 892-896.
[9]	梁辉勇, 韦秋慧, 丁亚, 彭小青, 姚静, 苏齐鉴. 虫草素抑制TNF-α诱导的人角质形成细胞系HaCaT增殖[J]. 基础医学与临床, 2023, 43(9): 1390-1393.
[10]	陈新军, 王卿语, 陈乐, 古春昱, 武卓. 紫檀茋减轻百草枯诱导的模型大鼠肺纤维化[J]. 基础医学与临床, 2023, 43(9): 1383-1389.
[11]	宋星明, 哈力沙·艾日肯江, 迪丽胡玛尔·阿布来提, 高颖. 内皮脂肪酶作为冠心病治疗靶点的研究进展[J]. 基础医学与临床, 2023, 43(9): 1443-1447.
[12]	江罗佳, 许海波. 短链脂肪酸乙酸钠减轻低氧/复氧诱导人肾小管上皮细胞系HK2损伤[J]. 基础医学与临床, 2023, 43(8): 1208-1214.
[13]	高源, 郑刚, 齐靖, 张凤. NLRP3炎性小体在心脏病发病中的作用研究进展[J]. 基础医学与临床, 2023, 43(7): 1162-1166.
[14]	季玮, 朱玥, 尧惠慈, 卢红艳. 白三烯C4及2型固有淋巴细胞在支气管肺发育不良中的变化及意义[J]. 基础医学与临床, 2023, 43(5): 711-716.
[15]	雷星煜, 冯雪松, 晁旭. 11β-HSD1在炎性反应、肝癌的发生发展与免疫中作用的研究进展[J]. 基础医学与临床, 2023, 43(5): 837-841.